China tightens biotechnology exports, allows licensing deals

China: China is a major global power with a rapidly expanding biotechnology and pharmaceutical sector that has become central to international drug development. The government is proposing to add several advanced biomedical technologies to its export control list as part of efforts to regulate biotech outflows. This policy maintains flexibility by allowing licensing arrangements, partnerships, and contract research with foreign drugmakers to sustain industry growth and global ties. Trade Policy: China's Ministry of Commerce released a draft proposal adding five biomedical technologies, including gene-level disease treatment platforms, to the export-control list. Industry Trend: Multinational pharmaceutical companies are increasingly securing global licensing deals for experimental drugs developed by Chinese firms in areas such as cancer and obesity treatments. International Collaboration: The proposed restrictions explicitly do not apply to licensing, partnerships, and contract research services involving the listed technologies.